BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

639 related articles for article (PubMed ID: 33995657)

  • 21. Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets.
    Spitzweg C; Bible KC; Hofbauer LC; Morris JC
    Lancet Diabetes Endocrinol; 2014 Oct; 2(10):830-42. PubMed ID: 24898835
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting Novel Sodium Iodide Symporter Interactors ADP-Ribosylation Factor 4 and Valosin-Containing Protein Enhances Radioiodine Uptake.
    Fletcher A; Read ML; Thornton CEM; Larner DP; Poole VL; Brookes K; Nieto HR; Alshahrani M; Thompson RJ; Lavery GG; Landa I; Fagin JA; Campbell MJ; Boelaert K; Turnell AS; Smith VE; McCabe CJ
    Cancer Res; 2020 Jan; 80(1):102-115. PubMed ID: 31672844
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selumetinib Activity in Thyroid Cancer Cells: Modulation of Sodium Iodide Symporter and Associated miRNAs.
    Wächter S; Wunderlich A; Greene BH; Roth S; Elxnat M; Fellinger SA; Verburg FA; Luster M; Bartsch DK; Di Fazio P
    Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30018229
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Manipulation of PBF/PTTG1IP phosphorylation status; a potential new therapeutic strategy for improving radioiodine uptake in thyroid and other tumors.
    Smith VE; Sharma N; Watkins RJ; Read ML; Ryan GA; Kwan PP; Martin A; Watkinson JC; Boelaert K; Franklyn JA; McCabe CJ
    J Clin Endocrinol Metab; 2013 Jul; 98(7):2876-86. PubMed ID: 23678037
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism.
    Filetti S; Bidart JM; Arturi F; Caillou B; Russo D; Schlumberger M
    Eur J Endocrinol; 1999 Nov; 141(5):443-57. PubMed ID: 10576759
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Robust Thyroid Gene Expression and Radioiodine Uptake Induced by Simultaneous Suppression of BRAF V600E and Histone Deacetylase in Thyroid Cancer Cells.
    Cheng W; Liu R; Zhu G; Wang H; Xing M
    J Clin Endocrinol Metab; 2016 Mar; 101(3):962-71. PubMed ID: 26751190
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: a novel therapeutic agent allowing noninvasive imaging and radioiodine therapy.
    Reddi HV; Madde P; McDonough SJ; Trujillo MA; Morris JC; Myers RM; Peng KW; Russell SJ; McIver B; Eberhardt NL
    Cancer Gene Ther; 2012 Sep; 19(9):659-65. PubMed ID: 22790962
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Digitalislike Compounds Restore hNIS Expression and Iodide Uptake Capacity in Anaplastic Thyroid Cancer.
    Tesselaar MH; Crezee T; Schuurmans I; Gerrits D; Nagarajah J; Boerman OC; van Engen-van Grunsven I; Smit JWA; Netea-Maier RT; Plantinga TS
    J Nucl Med; 2018 May; 59(5):780-786. PubMed ID: 29242405
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phosphoinositide-3-kinase inhibition induces sodium/iodide symporter expression in rat thyroid cells and human papillary thyroid cancer cells.
    Kogai T; Sajid-Crockett S; Newmarch LS; Liu YY; Brent GA
    J Endocrinol; 2008 Nov; 199(2):243-52. PubMed ID: 18762555
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dual inhibition of BRAF and MEK increases expression of sodium iodide symporter in patient-derived papillary thyroid cancer cells in vitro.
    Ullmann TM; Liang H; Moore MD; Al-Jamed I; Gray KD; Limberg J; Stefanova D; Buicko JL; Finnerty B; Beninato T; Zarnegar R; Min IM; Fahey TJ
    Surgery; 2020 Jan; 167(1):56-63. PubMed ID: 31585718
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MAPK Inhibition Requires Active RAC1 Signaling to Effectively Improve Iodide Uptake by Thyroid Follicular Cells.
    Faria M; Domingues R; Bugalho MJ; Matos P; Silva AL
    Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34831012
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radioiodine-Refractory Thyroid Cancer: Molecular Basis of Redifferentiation Therapies, Management, and Novel Therapies.
    Aashiq M; Silverman DA; Na'ara S; Takahashi H; Amit M
    Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31533238
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Radioiodine therapy in advanced differentiated thyroid cancer: Resistance and overcoming strategy.
    Liu Y; Wang J; Hu X; Pan Z; Xu T; Xu J; Jiang L; Huang P; Zhang Y; Ge M
    Drug Resist Updat; 2023 May; 68():100939. PubMed ID: 36806005
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The importance of sodium/iodide symporter (NIS) for thyroid cancer management.
    Carvalho DP; Ferreira AC
    Arq Bras Endocrinol Metabol; 2007 Jul; 51(5):672-82. PubMed ID: 17891230
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting GLI1 Transcription Factor for Restoring Iodine Avidity with Redifferentiation in Radioactive-Iodine Refractory Thyroid Cancers.
    Oh JM; Rajendran RL; Gangadaran P; Hong CM; Jeong JH; Lee J; Ahn BC
    Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406554
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhancement of sodium/iodide symporter expression in thyroid and breast cancer.
    Kogai T; Taki K; Brent GA
    Endocr Relat Cancer; 2006 Sep; 13(3):797-826. PubMed ID: 16954431
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of all-trans retinoic acid on sodium/iodide symporter expression, radioiodine uptake and gene expression profiles in a human anaplastic thyroid carcinoma cell line.
    Jeong H; Kim YR; Kim KN; Choe JG; Chung JK; Kim MK
    Nucl Med Biol; 2006 Oct; 33(7):875-82. PubMed ID: 17045167
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Outcomes of Radioactive Iodine Redifferentiation Therapy in Previously Iodine Refractory Differentiated Thyroid Cancers.
    Toro-Tobon D; Morris JC; Hilger C; Peskey C; Durski JM; Ryder M
    Thyroid; 2024 Jan; 34(1):70-81. PubMed ID: 37917101
    [No Abstract]   [Full Text] [Related]  

  • 39. Immunohistochemical analysis of sodium iodide symporter expression in metastatic differentiated thyroid cancer: correlation with radioiodine uptake.
    Castro MR; Bergert ER; Goellner JR; Hay ID; Morris JC
    J Clin Endocrinol Metab; 2001 Nov; 86(11):5627-32. PubMed ID: 11701745
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer.
    Romei C; Ciampi R; Faviana P; Agate L; Molinaro E; Bottici V; Basolo F; Miccoli P; Pacini F; Pinchera A; Elisei R
    Endocr Relat Cancer; 2008 Jun; 15(2):511-20. PubMed ID: 18509003
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.